Acadia court ruling supports Nuplazid exclusivity into 2030, says Mizuho

Mizuho says the yesterday’s Federal Court of Appeals ruling in favor of Acadia Pharmaceuticals (ACAD), upholding the validity of the ‘740 composition of matter patent, should provide further support that Acadia will likely maintain exclusivity of Nuplazid until the expiration of the patent on April 29, 2030. However, the stock price has already baked in this conclusion following the favorable January 2024 summary judgment and recently assumed Nuplazid exclusivity into February 2038 after the favorable district court ruling on Nuplazid’s 7721 patent in May, which covers the 34mg capsule formulation, the analyst tells investors in a research note.